Yanan Dong, DrPH

Manager, HEOR
AbbVie Inc

Poster(s):

• (66) Analysis on the net costs of administering a prior authorization policy for onabotulinumtoxinA in the chronic migraine population
  Wednesday, October 29, 2025

• (355) Real-world switch rates of injectable migraine preventive therapies in patients with chronic migraine
  Wednesday, October 29, 2025

• (356) Evaluation of unmet needs and quality-of-care indicators among patients with migraine in the United States: 2021–2022
  Wednesday, October 29, 2025